TGFBI Expression in Cancer Stromal Cells is Associated with Poor Prognosis and Hematogenous Recurrence in Esophageal Squamous Cell Carcinoma

Annals of Surgical Oncology

Volumn 23, Issue 1, 2016, Pages 282-289

  Ozawa, Daigo ^a   Yokobori, Takehiko ^a   Sohda, Makoto ^a   Sakai, Makoto ^a   Hara, Keigo ^a   Honjo, Hiroaki ^a   Kato, Hiroyuki ^b   Miyazaki, Tatsuya ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; BETAIG-H3 PROTEIN; SCLEROPROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL MIGRATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; TUMOR INVASION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; ENZYME IMMUNOASSAY; ESOPHAGUS TUMOR; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HEMATOLOGIC DISEASE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR RECURRENCE; WOUND HEALING;

AGED; APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STROMAL CELLS; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; WOUND HEALING;

EID: 84952630760     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4259-4     Document Type: Article

References (28)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
2. Parkin DM, Bray FI, Devesa SS. Cancer Burden in the Year 2000. The Global Picture. Eur J Cancer. 2001;37 Suppl 8:S4–66.
3. Wong FH, Huang CY, Su LJ, et al. Combination of Microarray Profiling and Protein-Protein Interaction Databases Delineates the Minimal Discriminators as a Metastasis Network for Esophageal Squamous Cell Carcinoma. Int J Oncol. 2009;34:117–128.
4. Kawamoto T, Noshiro M, Shen M, et al. Structural and phylogenetic analyses of RGD-CAP/Beta ig-h3, a Fasciclin-like adhesion protein expressed in chick chondrocytes. Biochim Biophys Acta. 1998;1395:288–92.
5. Schneider D, Kleeff J, Berberat PO, et al. Induction and Expression of Betaig-h3 in Pancreatic Cancer Cells. Biochim Biophys Acta. 2002;1588:1–6.
6. Nabokikh A, Ilhan A, Bilban M, et al. Reduced TGF-Beta1 expression and its target genes in human insulinomas. Exp Clin Endocrinol Diabetes. 2007;115:674–82.
7. Buckhaults P, Rago C, St Croix B, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res. 2001;61:6996–7001.
8. Tomioka H, Morita K, Hasegawa S, Omura K. Gene Expression Analysis by cDNA Microarray in Oral Squamous Cell Carcinoma. J Oral Pathol Med. 2006;35:206–11.
9. Fujiki K, Nakayasu K, Kanai A. Corneal Dystrophies in Japan. J Hum Genet. 2001;46:431–5.
10. Han B, Luo H, Raelson J, et al. TGFBI (BetaIG-H3) is a diabetes-risk gene based on mouse and human genetic studies. Hum Mol Genet. 2014; 23:4597–611.
11. Li B, Wen G, Zhao Y, et al. The role of TGFBI in mesothelioma and breast cancer: association with tumor suppression. BMC Cancer. 2012;12:239.
12. Wen G, Hong M, Li B, et al. Transforming growth factor-beta-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway. Int J Oncol. 2011;39:1001–9.
13. Kang S, Dong SM, Park NH. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer. Gynecol Oncol. 2010;118:58–63.
14. Shah JN, Shao G, Hei TK, Zhao Y. Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR. BMC Cancer. 2008;8:284.
15. Caren H, Djos A, Nethander M, et al. Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer. 2011;11:66.
16. Ahmed AA, Mills AD, Ibrahim AE, et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to Paclitaxel. Cancer Cell. 2007;12:514–27.
17. Ma C, Rong Y, Radiloff DR, et al. Extracellular matrix protein Betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 2008;22:308–21.
18. Lebdai S, Verhoest G, Parikh H, et al. Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma. Urol Oncol. 2014. doi:10.1016/j.urolonc.2014.06.005
19. Skonier J, Neubauer M, Madisen L, et al. cDNA cloning and sequence analysis of Beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-Beta. DNA Cell Biol. 1992;11:511–22.
20. Ivanov SV, Ivanova AV, Salnikow K, et al. Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun. 2008;370:536–40.
21. Montorfano I, Becerra A, Cerro R, et al. Oxidative stress mediates the conversion of endothelial cells into myofibroblasts via a TGF-Beta1 and TGF-Beta2-dependent pathway. Lab Invest 2014;94:1068–1082.
22. Costa A, Scholer-Dahirel A, Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Sem Cancer Biol. 2014;25:23–32.
23. Ween MP, Oehler MK, Ricciardelli C. Transforming growth factor-beta-induced protein (TGFBI)/(Betaig-H3): a matrix protein with dual functions in ovarian cancer. Int J Mol Sci. 2012;13:10461–77.
24. Jiang SS, Huang SF, Huang MS, et al. Dysregulation of the TGFBI gene is involved in the oncogenic activity of the nonsense mutation of hepatitis B virus surface gene sW182*. Biochim Biophys Acta. 2014;1842:1080–7.
25. Son HN, Nam JO, Kim S, Kim IS. Multiple FAS1 domains and the RGD motif of TGFBI act cooperatively to bind alphavbeta3 integrin, leading to anti-angiogenic and anti-tumor effects. Biochim Biophys Acta. 2013;1833:2378–88.
26. Lauden L, Siewiera J, Boukouaci W, et al. TGF-beta-induced (TGFBI) protein in melanoma: a signature of high metastatic potential. J Invest Dermatol. 2014;134:1675–85.
27. Klein CA. Cancer. The metastasis cascade. Science. 2008;321:1785–7.
28. Buga AM, Margaritescu C, Scholz CJ, et al. Transcriptomics of post-stroke angiogenesis in the aged brain. Front Again Neurosci. 2014;6:44.